US EditionImmunotherapy drug doubles survival rate for head and neck cancer in breakthrough trial
- A global trial presented at ASCO shows pembrolizumab helps head and neck cancer patients stay cancer-free for five years versus 2.5 years with standard care.
- Researchers tested pembrolizumab, an immunotherapy drug, after over 20 years of little progress in treating newly-diagnosed, locally-advanced head and neck cancer.
- The Keynote-689 trial, conducted at 192 sites in 24 countries with 714 patients, demonstrated that pembrolizumab lowered the risk of the cancer recurring in a different location by 10% after three years.
- Professor Kevin Harrington stated that pembrolizumab significantly extends the period patients remain free from disease, providing benefits that last several years beyond those achieved by existing standard treatments, and this improvement applies to all patients regardless of their immune marker status.
- These findings suggest pembrolizumab could improve survival for thousands with head and neck cancer, potentially changing treatment standards and reducing cancer spread risks significantly.
25 Articles
25 Articles
Saudi Arabia Advances Cancer Care with Potential Approval of Multikine Immunotherapy
In a pivotal development in cancer care, Saudi Arabia may become the first country in the world to approve CEL-SCI Corporation‘s investigational immunotherapy, Multikine, for commercial use in treating head and neck cancer. The US-based biotech company has submitted an application to the Saudi Food and Drug Authority (SFDA) for Breakthrough Medicine Designation, a fast-track regulatory pathway that could make Multikine available to patients as e…
Add-On Nivolumab Extends DFS in Locally Advanced Head and Neck Cancer
(MedPage Today) -- CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in certain patients with locally advanced head and neck squamous cell carcinoma (HNSCC), according...
Immune-boosting drug 'could change the world' for cancer patients
AN immune boosting drug can stave off throat cancer for years longer than current treatments, a trial found. Recovering head and neck cancer patients treated with pembrolizumab, also known as Keytruda, remained cancer-free for an average of five years. Immunotherapy drug pembrolizumab could help cancer patients live longer, scientists sayAssociated Press That was twice as long as the 2.5 years for patients given regular chemotherapy. The risk of…
Coverage Details
Bias Distribution
- 44% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
